PT971739E - Composicoes aquosas de adjuvante imunologico de monofosforil lipido a - Google Patents

Composicoes aquosas de adjuvante imunologico de monofosforil lipido a

Info

Publication number
PT971739E
PT971739E PT98915239T PT98915239T PT971739E PT 971739 E PT971739 E PT 971739E PT 98915239 T PT98915239 T PT 98915239T PT 98915239 T PT98915239 T PT 98915239T PT 971739 E PT971739 E PT 971739E
Authority
PT
Portugal
Prior art keywords
surfactant
lipid
derivative
attenuated
antigen
Prior art date
Application number
PT98915239T
Other languages
English (en)
Inventor
R Thomas Crane
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of PT971739E publication Critical patent/PT971739E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C07H13/06—Fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
PT98915239T 1997-04-01 1998-04-01 Composicoes aquosas de adjuvante imunologico de monofosforil lipido a PT971739E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83107397A 1997-04-01 1997-04-01

Publications (1)

Publication Number Publication Date
PT971739E true PT971739E (pt) 2004-12-31

Family

ID=25258229

Family Applications (1)

Application Number Title Priority Date Filing Date
PT98915239T PT971739E (pt) 1997-04-01 1998-04-01 Composicoes aquosas de adjuvante imunologico de monofosforil lipido a

Country Status (18)

Country Link
EP (1) EP0971739B1 (pt)
JP (1) JP5019494B2 (pt)
KR (1) KR100603884B1 (pt)
CN (2) CN1259052A (pt)
AT (1) ATE278419T1 (pt)
AU (1) AU743114B2 (pt)
BR (1) BR9811262A (pt)
CA (1) CA2284586C (pt)
DE (1) DE69826842T2 (pt)
ES (1) ES2227825T3 (pt)
HU (1) HUP0001403A3 (pt)
IL (2) IL132126A0 (pt)
NO (1) NO994760L (pt)
NZ (1) NZ338101A (pt)
PL (1) PL190237B1 (pt)
PT (1) PT971739E (pt)
TR (1) TR199902437T2 (pt)
WO (1) WO1998043670A2 (pt)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6491919B2 (en) 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
GB9706957D0 (en) 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
GB9820525D0 (en) 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
GB0000891D0 (en) * 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
DK1889630T3 (da) 2000-10-18 2012-03-05 Glaxosmithkline Biolog Sa Vacciner omfattende MAGE-antigen koblet til protein D-fragment
DE60239594D1 (de) 2001-02-23 2011-05-12 Glaxosmithkline Biolog Sa Influenza vakzinzusammensetzungen zur intradermaler verabreichung
US20030031684A1 (en) 2001-03-30 2003-02-13 Corixa Corporation Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
TWI228420B (en) 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
US20100221284A1 (en) 2001-05-30 2010-09-02 Saech-Sisches Serumwerk Dresden Novel vaccine composition
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
PT1828378E (pt) * 2004-12-17 2014-10-10 Staat Der Nederlanden Vert Door De Minister Van Vws Ministerie Van Volksgezondheid Welzijn En Sport Deacilação de lps em bactérias de gram negativo
GB0503337D0 (en) 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
GB0504436D0 (en) 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
SI2457926T1 (sl) 2005-04-29 2015-01-30 Glaxosmithkline Biologicals S.A. Nov postopek za preprečevanje ali zdravljenje infekcije z M. tuberculosis
AU2006274647B2 (en) * 2005-08-02 2013-01-10 Novartis Vaccines And Diagnostics Srl Reducing interference between oil-containing adjuvants and surfactant-containing antigens
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US8018440B2 (en) 2005-12-30 2011-09-13 Microsoft Corporation Unintentional touch rejection
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
KR101378872B1 (ko) 2006-09-26 2014-04-11 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) 합성 애주번트를 함유하는 백신 조성물
US8836648B2 (en) 2009-05-27 2014-09-16 Microsoft Corporation Touch pull-in gesture
SI2437753T1 (sl) 2009-06-05 2016-12-30 Infectious Disease Research Institute Sintetični glukopiranozil-lipidni adjuvansi in cepivni sestavki, ki jih vsebujejo
FR2954703B1 (fr) 2009-12-28 2013-12-13 Chu Nantes Agonistes des recepteurs tlr 4 et 9 pour prevenir les complications septiques de l'immunodepression post-traumatique chez les patients hospitalises pour traumatismes severes
US8261213B2 (en) 2010-01-28 2012-09-04 Microsoft Corporation Brush, carbon-copy, and fill gestures
US9411504B2 (en) 2010-01-28 2016-08-09 Microsoft Technology Licensing, Llc Copy and staple gestures
US9519356B2 (en) 2010-02-04 2016-12-13 Microsoft Technology Licensing, Llc Link gestures
US8799827B2 (en) 2010-02-19 2014-08-05 Microsoft Corporation Page manipulations using on and off-screen gestures
US9310994B2 (en) 2010-02-19 2016-04-12 Microsoft Technology Licensing, Llc Use of bezel as an input mechanism
US9367205B2 (en) 2010-02-19 2016-06-14 Microsoft Technolgoy Licensing, Llc Radial menus with bezel gestures
US9454304B2 (en) 2010-02-25 2016-09-27 Microsoft Technology Licensing, Llc Multi-screen dual tap gesture
US9075522B2 (en) 2010-02-25 2015-07-07 Microsoft Technology Licensing, Llc Multi-screen bookmark hold gesture
US8751970B2 (en) 2010-02-25 2014-06-10 Microsoft Corporation Multi-screen synchronous slide gesture
US8707174B2 (en) 2010-02-25 2014-04-22 Microsoft Corporation Multi-screen hold and page-flip gesture
US8689123B2 (en) 2010-12-23 2014-04-01 Microsoft Corporation Application reporting in an application-selectable user interface
US8612874B2 (en) 2010-12-23 2013-12-17 Microsoft Corporation Presenting an application change through a tile
US9423951B2 (en) 2010-12-31 2016-08-23 Microsoft Technology Licensing, Llc Content-based snap point
US9383917B2 (en) 2011-03-28 2016-07-05 Microsoft Technology Licensing, Llc Predictive tiling
GB201106357D0 (en) 2011-04-14 2011-06-01 Pessi Antonello Composition and uses thereof
AU2012243039B2 (en) 2011-04-08 2017-07-13 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
US9158445B2 (en) 2011-05-27 2015-10-13 Microsoft Technology Licensing, Llc Managing an immersive interface in a multi-application immersive environment
US9104307B2 (en) 2011-05-27 2015-08-11 Microsoft Technology Licensing, Llc Multi-application environment
US9104440B2 (en) 2011-05-27 2015-08-11 Microsoft Technology Licensing, Llc Multi-application environment
US9658766B2 (en) 2011-05-27 2017-05-23 Microsoft Technology Licensing, Llc Edge gesture
US9557909B2 (en) 2011-09-09 2017-01-31 Microsoft Technology Licensing, Llc Semantic zoom linguistic helpers
US9244802B2 (en) 2011-09-10 2016-01-26 Microsoft Technology Licensing, Llc Resource user interface
US9146670B2 (en) 2011-09-10 2015-09-29 Microsoft Technology Licensing, Llc Progressively indicating new content in an application-selectable user interface
AU2012308149A1 (en) 2011-09-12 2014-03-27 Sheena Mary Geraldine MCCORMACK Methods and compositions for raising an immune response to HIV
PT2850431T (pt) 2012-05-16 2018-07-23 Immune Design Corp Vacinas para hsv-2
EP2666785A1 (en) 2012-05-23 2013-11-27 Affiris AG Complement component C5a-based vaccine
EP2703483A1 (en) 2012-08-29 2014-03-05 Affiris AG PCSK9 peptide vaccine
WO2014043189A1 (en) 2012-09-14 2014-03-20 The Regents Of The University Of Colorado, A Body Corporate Conditionally replication deficient herpes viruses and use thereof in vaccines
US9582122B2 (en) 2012-11-12 2017-02-28 Microsoft Technology Licensing, Llc Touch-sensitive bezel techniques
EP3711768A1 (en) 2013-04-18 2020-09-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
US9477337B2 (en) 2014-03-14 2016-10-25 Microsoft Technology Licensing, Llc Conductive trace routing for display and bezel sensors
AU2015238512B2 (en) * 2014-03-26 2018-02-01 Glaxosmithkline Biologicals S.A. Mutant staphylococcal antigens
EP3169699A4 (en) 2014-07-18 2018-06-20 The University of Washington Cancer vaccine compositions and methods of use thereof
EP3138579A1 (en) 2015-09-05 2017-03-08 Biomay Ag Fusion protein for use in the treatment of a hepatitis b virus infection
GB201614799D0 (en) 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
EP3295956A1 (en) 2016-09-20 2018-03-21 Biomay Ag Polypeptide construct comprising fragments of allergens
CN111315406A (zh) 2017-09-08 2020-06-19 传染病研究所 包括皂苷的脂质体调配物及其使用方法
WO2019175145A1 (en) 2018-03-12 2019-09-19 Janssen Vaccines & Prevention B.V. Vaccines against urinary tract infections
EP3569612A1 (en) 2018-05-18 2019-11-20 Biomay Ag Treatment and prevention of house dust mite allergies
EP3941516A1 (en) 2019-03-18 2022-01-26 Janssen Pharmaceuticals, Inc. Bioconjugates ofe col! o-antigen polysaccharides. methods of production thereof. andmethods of use thereof
IL286467B2 (en) 2019-03-18 2026-02-01 Janssen Pharmaceuticals Inc Methods for producing bioconjugates of polysaccharides E. coli o-antigen, preparations thereof and methods for using them
IL291821A (en) 2019-10-02 2022-06-01 Janssen Vaccines & Prevention Bv Staphylococcus peptides and methods of use
MY209568A (en) 2020-01-16 2025-07-22 Janssen Pharmaceuticals Inc Fimh mutant, compositions therewith and use thereof
AU2021342797B2 (en) 2020-09-17 2024-02-08 Janssen Pharmaceuticals, Inc. Multivalent vaccine compositions and uses thereof
JP7532672B2 (ja) 2021-01-12 2024-08-13 ヤンセン ファーマシューティカルズ，インコーポレーテッド ＦｉｍＨ変異体、それを含む組成物、及びその使用
KR20230164108A (ko) 2021-04-01 2023-12-01 얀센 파마슈티칼즈, 인코포레이티드 E. coli O18 생물접합체의 생산
US20240180940A1 (en) * 2021-05-27 2024-06-06 Revelation Biosciences, Inc. Mpla compositions and methods of use
CN121221758B (zh) * 2025-12-02 2026-03-03 华诺泰生物医药科技(成都)有限公司 一种即用型稳定3d-mla佐剂溶液的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5068191A (en) * 1989-08-31 1991-11-26 The Biomembrane Institute Purified histo-blood group a glycosyltransferase and antibodies thereto
US5552141A (en) * 1991-10-30 1996-09-03 Ribi; Hans O. Polymeric immunological adjuvants
SG48309A1 (en) * 1993-03-23 1998-04-17 Smithkline Beecham Biolog Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a

Also Published As

Publication number Publication date
HK1026613A1 (en) 2000-12-22
CA2284586C (en) 2011-02-08
JP5019494B2 (ja) 2012-09-05
PL336698A1 (en) 2000-07-03
CN1575815A (zh) 2005-02-09
AU6947398A (en) 1998-10-22
NZ338101A (en) 2002-03-28
HUP0001403A3 (en) 2003-05-28
CN1326564C (zh) 2007-07-18
KR20010005882A (ko) 2001-01-15
EP0971739B1 (en) 2004-10-06
WO1998043670A3 (en) 1998-12-30
DE69826842D1 (de) 2004-11-11
IL132126A0 (en) 2001-03-19
IL132126A (en) 2006-10-05
BR9811262A (pt) 2000-10-17
HUP0001403A2 (hu) 2000-09-28
CN1259052A (zh) 2000-07-05
NO994760D0 (no) 1999-09-30
KR100603884B1 (ko) 2006-07-24
PL190237B1 (pl) 2005-11-30
JP2001526640A (ja) 2001-12-18
CA2284586A1 (en) 1998-10-08
WO1998043670A2 (en) 1998-10-08
AU743114B2 (en) 2002-01-17
EP0971739A2 (en) 2000-01-19
DE69826842T2 (de) 2005-11-24
ATE278419T1 (de) 2004-10-15
ES2227825T3 (es) 2005-04-01
TR199902437T2 (xx) 2000-01-21
NO994760L (no) 1999-11-26

Similar Documents

Publication Publication Date Title
NO994760L (no) Vandige immunologiske adjuvanspreparat av monofosforyllipid A
DE60037514D1 (de) Wässerige immunologische adjuvantzusammensetzungen aus monophosphoryllipid a
US6500453B2 (en) Polymerizable fatty acids, phospholipids and polymerized liposomes therefrom
CA1047921A (en) Liposomes used as adjuvants in vaccines
US10988500B2 (en) Lipid A mimics, methods of preparation, and uses thereof
HUP0004147A2 (hu) Amino-alkil-glükózamin-foszfát vegyületek és adjuvánsként, valamint immuneffektorként való alkalmazásuk
GB2124618A (en) Aliphatic hydroxy amides
PE20000574A1 (es) Articulos, metodos y composiciones para limpiar productos agricolas y proteina animal comestible
Blom et al. Sucrose fatty acid sulphate esters as novel vaccine adjuvants: effect of the chemical composition
AU751051B2 (en) Adjuvant comprising pulmonary surfactant
WATARAI et al. Antibody response in the intestinal tract of mice orally immunized with antigen associated with liposomes
ES2084348T3 (es) N-((4,5-dihidroxi- y 4,5,8-trihidroxi-9,10-dihidro-9,10-dioxo-2-antracen-il)carbonil)aminoacidos utiles en la terapia de afecciones osteoarticulares.
US20050266066A1 (en) Phospholipid membrane preparation
KR0178422B1 (ko) 한탄 바이러스의 펩타이드 항원을 함유하는 리포좀
KR0173366B1 (ko) B형 간염 바이러스의 펩타이드 항원을 함유하는 리포좀
DE69505236T2 (de) Liposomen und deren verwendung insbesondere zur herstellung immunomodulatorischer mittel
JPH08183742A (ja) 経鼻ワクチンリポソーム
KR0173365B1 (ko) C형 간염 바이러스의 펩타이드 항원을 함유하는 리포좀
KR100189701B1 (ko) B형 간염 바이러스의 x 단밸직 유래의 펩타이드 항원을 함유하는 리포좀
KR100406503B1 (ko) 폐렴구균성 표면 접착단백질의 가용화용 조성물, 가용화용액상제형, 및 가용화용 분말제형, 이들 각각의 제조방법및 백신
CO4180620A1 (es) Proceso para preparar formulaciones solidas que contienen tensioactivos de oxido de amina, que comprende una sal so- luble en agua de acido maleico-oxido de amina
JPH0292996A (ja) アジュバントおよび脂質を含む複合体